Trials / Active Not Recruiting
Active Not RecruitingNCT06137768
A Trial of HRS-5965 Tablets in Primary IgA Nephropathy
A Trial to Evaluate the Efficacy and Safety of HRS-5965 Tablets in Primary IgA Nephropathy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 123 (actual)
- Sponsor
- Chengdu Suncadia Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is being conducted to evaluate the efficacy, and safety of HRS-5965 tablets for primary IgA nephropathy. To explore the effective dosage of HRS-5965 tablets for primary IgA nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HRS-5965 | HRS-5965 |
| DRUG | Placebo | Placebo. |
Timeline
- Start date
- 2023-12-19
- Primary completion
- 2024-12-01
- Completion
- 2025-08-31
- First posted
- 2023-11-18
- Last updated
- 2025-04-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06137768. Inclusion in this directory is not an endorsement.